Clinical trial
An Effectiveness and Safety Study of CONCERTA® (Methylphenidate Hydrochloride)…
NCT00249353 · McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Industry · Completed
Key facts
| NCT number | NCT00249353 |
|---|---|
| Title | An Effectiveness and Safety Study of CONCERTA® (Methylphenidate Hydrochloride) in the Treatment of Adolescents With Attention Deficit Hyperactivity Disorder |
| Official title | An Evaluation of the Safety and Effectiveness of CONCERTA® (Methylphenidate Hydrochloride), up to 72 mg Daily, in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) |
| Lead sponsor | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Attention Deficit Disorder With Hyperactivity |
| Intervention type | Drug |
| Interventions | methylphenidate hydrochloride |
| Enrollment | 220 |
| Start date | Mar 1, 2002 |
| Completion | Oct 1, 2002 |
| First posted | Nov 7, 2005 |
| Last update posted | Apr 28, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: